NasdaqGM:RMTI

Stock Analysis Report

Executive Summary

Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Rockwell Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.2%

RMTI

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

-41.5%

RMTI

15.6%

US Medical Equipment

6.9%

US Market

Return vs Industry: RMTI underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: RMTI underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

RMTIIndustryMarket
7 Day-1.2%1.9%0.4%
30 Day-25.5%-1.6%-1.2%
90 Day-17.9%0.01%-0.4%
1 Year-41.5%-41.5%16.5%15.6%9.3%6.9%
3 Year-59.3%-59.3%72.1%66.9%45.8%36.4%
5 Year-73.5%-73.5%125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is Rockwell Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Rockwell Medical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: RMTI ($2.48) is trading below our estimate of fair value ($17)

Significantly Undervalued: RMTI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RMTI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: RMTI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate RMTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RMTI is overvalued based on its PB Ratio (5.3x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Rockwell Medical forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

66.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RMTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: RMTI is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: RMTI's loss is forecast to worsen by 0% next year.

Revenue vs Market: RMTI's revenue (33% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: RMTI's revenue (33% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if RMTI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Rockwell Medical performed over the past 5 years?

-11.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: RMTI is unprofitable, and losses have increased over the past 5 years at a rate of -11.6% per year.

Accelerating Growth: Unable to compare RMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RMTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: RMTI has a negative Return on Equity (-112.59%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: RMTI is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: RMTI is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Rockwell Medical's financial position?


Financial Position Analysis

Short Term Liabilities: RMTI's short term assets ($48.3M) exceeds its short term liabilities ($14.8M)

Long Term Liabilities: RMTI's short term assets (48.3M) exceeds its long term liabilities (12.6M)


Debt to Equity History and Analysis

Debt Level: RMTI's debt to equity ratio (6.4%) is considered satisfactory

Reducing Debt: RMTI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: RMTI has a low level of unsold assets or inventory.

Debt Coverage by Assets: RMTI's debt is covered by short term assets (assets are 25.287380x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RMTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RMTI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Rockwell Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate RMTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RMTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if RMTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RMTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RMTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Rockwell Medical's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Stuart Paul (59yo)

1.1yrs

Tenure

US$7,483,803

Compensation

Mr. Stuart Paul is Chief Executive Officer and Director at Rockwell Medical, Inc. since September 04, 2018 and also serves as it's President. He served as the President of Asia & Pacific (APAC) at Gambro R ...


CEO Compensation Analysis

Compensation vs. Market: Stuart has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Stuart's compensation with company performance.


Management Age and Tenure

1.0yrs

Average Tenure

55.5yo

Average Age

Experienced Management: RMTI's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Age and Tenure

5.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: RMTI's board of directors are considered experienced (5 years average tenure).


Insider Trading

Insider Buying: RMTI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$5,04102 Aug 19
Matthew Curfman
EntityIndividual
Shares1,904
Max PriceUS$2.66
BuyUS$97626 Jul 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares319
Max PriceUS$3.06
BuyUS$8,07226 Jul 19
Matthew Curfman
EntityIndividual
Shares2,579
Max PriceUS$3.13
BuyUS$475,88123 Jul 19
Richmond Brothers, Inc.
EntityCompany
Shares161,457
Max PriceUS$2.99
BuyUS$16,81010 Jul 19
Matthew Curfman
EntityIndividual
Shares5,519
Max PriceUS$3.05
BuyUS$11,14210 Jul 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares3,658
Max PriceUS$3.05
BuyUS$1,83710 Jul 19
David Richmond
EntityIndividual
Shares603
Max PriceUS$3.05
BuyUS$29,70003 Jul 19
Stuart Paul
EntityIndividual
Role
Chief Executive Officer
President
Shares10,000
Max PriceUS$2.97
BuyUS$30,60003 Jul 19
Angus Smith
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares10,000
Max PriceUS$3.06
SellUS$026 Jun 19
Richmond Brothers, Inc.
EntityCompany
Shares17,863
Max PriceUS$5.11
BuyUS$026 Jun 19
Richmond Brothers, Inc.
EntityCompany
Shares50,775
Max PriceUS$5.58
BuyUS$7,00026 Jun 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares1,240
Max PriceUS$5.65
BuyUS$11,97913 May 19
Matthew Curfman
EntityIndividual
Shares2,122
Max PriceUS$5.65
BuyUS$11,37513 May 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares2,015
Max PriceUS$5.65
BuyUS$2,85713 May 19
David Richmond
EntityIndividual
Shares506
Max PriceUS$5.65
BuyUS$8,68229 Mar 19
David Richmond
EntityIndividual
Shares1,554
Max PriceUS$5.59
BuyUS$1,27429 Mar 19
Matthew Curfman
EntityIndividual
Shares228
Max PriceUS$5.59
BuyUS$22,83329 Mar 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares4,087
Max PriceUS$5.59
SellUS$35,31028 Mar 19
Richmond Brothers, Inc.
EntityCompany
Shares7,863
Max PriceUS$6.60
BuyUS$57,89328 Mar 19
Richmond Brothers, Inc.
EntityCompany
Shares15,114
Max PriceUS$6.55
BuyUS$43,24528 Mar 19
Richmond Brothers 401(K) Profit Sharing Plan
EntityCompany
Shares7,655
Max PriceUS$6.14

Ownership Breakdown


Management Team

  • Ajay Gupta (61yo)

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 13.9yrs
    • Compensation: US$954.42k
  • Stuart Paul (59yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$7.48m
  • Jim McCarthy

    Senior Vice President of Business & Corporate Development

    • Tenure: 1.1yrs
  • Ray Pratt (68yo)

    Chief Medical Officer

    • Tenure: 7.5yrs
    • Compensation: US$965.87k
  • Angus Smith (36yo)

    Chief Financial Officer

    • Tenure: 0.9yrs
    • Compensation: US$1.45m
  • David Kull (52yo)

    Executive Officer

    • Tenure: 0.3yrs
  • Anne Boardman

    Vice President of Sales and Strategic Accounts

    • Tenure: 1yrs
  • Mike DeYoung

    Vice President of Operations

    • Tenure: 0.8yrs
  • Michael Costello

    General Counsel

    • Tenure: 0yrs
  • Paul McGarry (51yo)

    VP, Corporate Controller & Principal Accounting Officer

    • Tenure: 0.3yrs

Board Members

  • John Cooper (60yo)

    Director

    • Tenure: 2.1yrs
    • Compensation: US$286.19k
  • Robin Smith (54yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$193.16k
  • Lisa Colleran (61yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$246.15k
  • Ben Wolin (43yo)

    Chairman

    • Tenure: 1.6yrs
    • Compensation: US$306.85k
  • Ajay Gupta (61yo)

    Chief Scientific Officer & Member of Scientific Advisory Board

    • Tenure: 13.9yrs
    • Compensation: US$954.42k
  • Rajiv Agarwal

    Member of Scientific Advisory Board

    • Tenure: 13.9yrs
  • Stuart Paul (59yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$7.48m
  • Iain MacDougall

    Member of Scientific Advisory Board

    • Tenure: 9.2yrs
  • Alvin Crumbliss

    Member of Scientific Advisory Board

    • Tenure: 8.5yrs
  • Francesco Locatelli

    Member of Scientific Advisory Board

    • Tenure: 6.8yrs

Company Information

Rockwell Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Rockwell Medical, Inc.
  • Ticker: RMTI
  • Exchange: NasdaqGM
  • Founded: 1994
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$158.285m
  • Shares outstanding: 63.82m
  • Website: https://www.rockwellmed.com

Number of Employees


Location

  • Rockwell Medical, Inc.
  • 30142 Wixom Road
  • Wixom
  • Michigan
  • 48393
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RMTINasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJan 1998
RWMDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1998

Biography

Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and he ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 23:39
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.